Navigation Links
Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
Date:9/17/2007

First internal candidate to enter Phase 2 clinical development

PRINCETON, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the initiation of a Phase 2a clinical study of PS433540, the company's lead internal product candidate. PS433540 is a dual-acting angiotensin and endothelin receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically proven mechanisms of action in a single compound. The compound works by selectively blocking the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. Preclinical studies have shown that PS433540 is highly selective for the AII receptor sub-type 1 and the ET receptor sub-type A. As such PS433540 combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same molecule. There are considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

The objective of the Phase 2a randomized, double-blind, placebo- controlled, parallel-group study is to evaluate the compound's safety and efficacy in subjects with Stage I and Stage II hypertension. This multi- center trial is expected to enroll 170 subjects. After a lead-in period, patients will be randomized into three study arms (placebo and two active arms
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... in the research, development and commercialization of prescription ophthalmic ... million advance from Hercules Technology Growth Capital, Inc. (NYSE: ... second and final advance under the Loan and Security ... Kingdom , Alimera Sciences Limited, entered into with ...
(Date:9/30/2014)... 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... the company,s Bridgewater, New Jersey ... and Drug Administration (FDA) relating to an inspection in ... Sculptra Aesthetic injectable, which was divested to Galderma S.A. ... of Valeant,s contract manufacturers (rather than Valeant,s own internal ...
(Date:9/30/2014)... Sept. 30, 2014  Based on its recent ... & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), ... 2014 North American Frost & Sullivan Award for ... along with a focus on innovation and improving ... in tissue-based cancer diagnostic solutions for patients worldwide. ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... launches integrated, multi-channel offerings for three fast-growing export sectors -- HONG KONG, Oct. 26 /PRNewswire-Asia/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ...
... Oct. 25 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... quarter ended September 30, 2010, on Monday, November 1, ... will host a conference call and webcast on Monday, ... discuss the Company,s third quarter results and corporate developments. ...
Cached Medicine Technology:Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 2Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 3Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 4Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 5Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 6Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 7Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 8Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 9Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call 2Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call 3
(Date:9/30/2014)... 2014 A new study of ... the impact of stress on metabolism after eating a high-fat ... from a fast food restaurant, about 930 calories and 60 ... 20 minutes every hour for 7 hours, conducting the study ... who had experienced a stressful event in their lives during ...
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... 2014 Elevate , the latest product ... in and out of the gym by providing natural ingredients ... attention of Shane Michaels, prompting an investigative review. , ... reason most people simply just don’t have the ability to ... at work, getting the motivation to finish a project, or ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 With ... viral strains emerging every day, it’s a perfect ... The EnviroShield system is an electro-static disinfectant ... applications to surface normally missed with spray-on disinfectant ... nozzle that adds an electrostatic negative charge to ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Bifidobacteria, the ... with age, poor diet, and stress, so a high ... Each capsule of Ultimate Flora™ Men’s Complete ... cultures from 7 Bifidobacteria strains to support a healthy ... to build up, and 32 billion cultures from 7 ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
... WASHINGTON, Feb. 5 Following is a statement,by Daniel ... his last budget, the president had an opportunity to ... nation,s No. 1 killer,and costliest disease. Instead, his proposal ... cure. We,re making steady progress in combating heart,disease and ...
... precisely which bugs in the gut are involved in which ... bugs living in seven members of the same Chinese family. ... and trillions live symbiotically inside the human body. Different people ... them. , The makeup of each persons gut microflora ...
... West Pharmaceutical,Services, Inc. (NYSE: WST ) today ... Executive Officer, and William Federici, Chief,Financial Officer, will be ... 3:00 p.m. on February 11, 2008 in New York ... will be posted on the,investor link of the Company,s ...
... Compliance Corp. (OTC,Bulletin Board: SCOM) ("Sharps" or the ... small quantity generators of medical,waste, today announced that ... Officer, will present at the RedChip Small-Cap Investor,Conference ... approximately,10:10 a.m. MST (12:10 p.m. EST) on Thursday, ...
... LAKE FOREST, Ill., Feb. 5 BIOSAFE Laboratories, ... and Glycemion, the,United States distributor, have announced the ... use in schools to help identify diabetic and,pre-diabetic ... a two-part process comprised of an immediate fasting ...
... Rapid Growth, WAYNE, Pa., Feb. 5 ... communications,platform specifically designed for the biomedical research community,announced ... of myBW (or myBioWizard), a,unique personalization tool available ... now provides biomedical researchers access to approximately,half a ...
Cached Medicine News:Health News:Statement by Daniel W. Jones, M.D., American Heart Association President on President Bush's FY 2009 Budget Proposal 2Health News:Bug guts map brings scientists closer to understanding different bugs' role in the body 2Health News:Bug guts map brings scientists closer to understanding different bugs' role in the body 3Health News:West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona 2Health News:BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessment Kits to U.S. School Children 2Health News:BioWizard Offers Conference Abstracts with the Launch of myBW 2Health News:BioWizard Offers Conference Abstracts with the Launch of myBW 3
... Two Large Working Channels; 33 cm Working ... is the smallest ureteroscope with two large ... The ACMI MICRO-6 Ureteroscope reduces patient trauma ... or no dilation or general anesthesia. It ...
Smooth, contoured visual obturator provides less traumatic insertion through the urethra and into the bladder....
Semi-Rigid Ureteroscope...
... features a tip diameter of only ... up/down angulation range of 180 for ... areas.,For improved observation, a new optical ... reusable 11.7Fr (3.9mm) sheath dilator, 0.035" ...
Medicine Products: